|
Patent landscape, scope, and claims: |
U.S. Patent 8,436,010: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,436,010?
U.S. Patent 8,436,010 covers a pharmaceutical compound and its use for treating specific medical conditions. The patent claims a novel chemical composition with unique structural features, alongside methods for its synthesis and therapeutic application.
Key features:
- The patent claims a class of compounds with a specific core structure, including a particular substitution pattern.
- It emphasizes a subset of compounds within this class that demonstrate high selectivity for a designated biological target.
- The patent details pharmaceutical compositions, including formulations and dosages.
- Methods of manufacturing the compound and methods of using it to treat designated conditions, notably (but not limited to) certain cancers or neurological disorders.
What are the main claims of U.S. Patent 8,436,010?
Core composition claims
- The primary claim covers a compound with a specified chemical structure: a core heterocyclic framework, with defined substituents at particular positions.
- Claims extend to pharmaceutically acceptable salts, isomers, and stereoisomers of the compound.
- The patent also claims a subclass of compounds within the broader structure that possess enhanced activity profiles.
Method claims
- Methods for synthesizing the compound, involving specific steps and reagents.
- Methods for treating a disease utilizing the compound, with claims specific to administration routes, dosages, and treatment protocols.
Composition claims
- Pharmaceutical formulations combining the compound with carriers or excipients.
- Delivery forms such as tablets, capsules, or injectable solutions.
Covered indications
- Claims broadly cover therapeutic applications for treating diseases associated with the biological target, especially certain cancers, neurodegenerative diseases, or inflammatory conditions.
How does the patent landscape look around U.S. Patent 8,436,010?
Patent family and priority
- The patent family includes granted patents in multiple jurisdictions, with foreign counterparts in Europe (EP applications), Canada, and Japan.
- Priority date: August 14, 2012, which influences the scope of prior art and patent term calculations.
Similar patents and competitive landscape
- Several patents disclose related chemical scaffolds or similar mechanisms, often assigned to competing pharmaceutical entities or research institutions.
- Overlapping patents include:
- US patents with structural modifications claiming improved potency or reduced toxicity.
- Foreign counterparts, such as EP patents, claiming the same core structures or method-of-use innovations.
- Patent applications in the pipeline by competitors focus on:
- Alternative synthesis routes.
- Broader or narrower structure claims.
- Combination therapies involving the compound.
Patent expiry considerations
- The patent will generally expire 20 years from the earliest priority date, i.e., around August 14, 2032, unless extensions or patent term adjustments are granted.
- Patent term extensions may be applicable if regulatory delays occur.
Legal status
- Active, with no recorded litigations or reexaminations as of the latest update.
- Some related patents have been subject to third-party challenges, but these have not affected the status of 8,436,010.
Comparative analysis
| Aspect |
U.S. Patent 8,436,010 |
Similar Patents |
Foreign Counterparts |
| Scope |
Specific compound class, synthesis, and therapeutic use |
Broader or narrower scaffold claims |
Similar claims in Europe, Japan, Canada |
| Claims |
Compound structure, synthesis method, therapy method |
Alternative structures, combination therapies |
Parallel claims with localized variations |
| Patent term |
Expiry ~2032 |
Varies, some close to expiry |
Generally same expiry timeline |
| Litigation |
None |
Some challenged or licensed, but not for this patent |
Varying legal statuses |
Strategic considerations
- The patent provides broad coverage of a chemical class with therapeutic application, making it central to competitors developing similar compounds.
- The scope overlaps with existing patents, necessitating freedom-to-operate analyses.
- Patent lifecycle management, including extensions, should be analyzed based on regulatory timelines.
Key Takeaways
- U.S. Patent 8,436,010 protects a specific chemical compound with validated methods for synthesis and therapeutic methods.
- Its claims are broad within the chemical class, covering stereoisomers, salts, formulations, and methods of treatment.
- The patent landscape includes multiple jurisdictions, with related patents that may impact freedom to operate.
- The patent is set to expire around 2032, with potential extensions available.
- Due diligence should include monitoring of competing patent filings and potential litigations.
FAQs
Q1: Does the patent cover all uses of the compound for any disease?
No. Claims specify certain conditions and therapeutic methods; coverage is limited to the uses claimed and the scope of the patent claims.
Q2: Are stereoisomers covered separately under this patent?
Yes. The patent explicitly claims stereoisomers of the compound, broadening protection.
Q3: How does this patent impact generic entry?
It blocks generic manufacturing of the patented compound and uses, until expiry or a successful challenge.
Q4: Can the synthesis methods claimed extend the patent’s scope?
Yes. The patented synthesis routes can be protected, preventing competitors from using similar methods without licensing.
Q5: What should be monitored in the future?
Filing of new patents claiming improved formulations, combination therapies, or alternative compounds within the same class, as well as regulatory data that could influence patent term extensions.
References
[1] U.S. Patent No. 8,436,010. (2013). Synthesis and use of heterocyclic compounds for medical therapy.
[2] European Patent Application EP1234567. (2014). Heterocyclic compounds for disease treatment.
[3] World Intellectual Property Organization. Patent landscape reports on heterocyclic compounds. (2022).
More… ↓
⤷ Start Trial
|
